Hematology-Oncology Edition

Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Hematology/Oncology Drug News

Teva, Mylan, Dr. Reddy's Launch Clopidogrel Tablets

May 18, 2012

Teva Pharmaceuticals has announced the introduction and availability of Clopidogrel Tablets, an AB rated and bioequivalent product to Plavix Tablets (Bristol-Myers Squibb and Sanofi Aventis). Clopidogrel Tablets 75mg are available from Teva in 30, 90, and 500 count bottles.

Adjuvant Radiochemotherapy Has Lasting Benefit in Gastric Cancer

May 18, 2012

Ten-year data from the Southwestern Oncology Group-directed Intergroup Study 0116 confirm the benefits of adjuvant radiochemotherapy after gastric cancer resection in terms of overall survival (OS) and relapse-free survival (RFS).

ASCO: Crizotinib Tolerated, Active in Pediatric Patients

May 18, 2012

For pediatric patients with tumors that have genetic aberrations in the anaplastic lymphoma kinase (ALK) gene, crizotinib is well tolerated and has antitumor activity.

ASCO: Oncologists Better ID Long-Term Effects of Chemo

May 18, 2012

Most oncologists can identify the main late or long-term effects (LEs) of chemotherapy drugs, but primary care physicians (PCPs) are less likely to be able to do so.

Fentanyl Sublingual Spray Shown to be Effective in Breakthrough Cancer Pain

May 18, 2012

Fentanyl sublingual spray can be safely titrated to an effective dose in patients with breakthrough cancer pain, a study presented at the American Pain Society's 31st Annual Scientific Meeting has found.

VORAXAZE

5/7/2012

BTG International

Pharmacological Class: Carboxypeptidase enzyme.

Active Ingredient(s): Glucarpidase; 1,000 Units/vial; lyophilized powder for IV injection after reconstitution; preservative-free.

Indication: Treatment of toxic plasma methotrexate (MTX) concentrations (>1 micromole per liter) in patients with delayed MTX clearance due to impaired renal function.

Daily Oncology News

Conference News

Round-up

more >

Hematology/Oncology CME/CE: Courses

Using ESAs in patients with cancer-related anemia

0.75/ CE for Nurses

Based on data regarding the risks associated with erythropoietinstimulating agents (ESAs), the FDA recommended a Risk Evaluation Mitigation Strategy (REMS) program for these agents. Nurses play an important role in ensuring that prescribed treatment plans are appropriate for a particular patient (eg, laboratory parameters are appropriate).

Troubleshooting complications of vascular access devices

1.50/ CE for Nurses

The most common complications associated with VADs are catheter-related infections and occlusions. Diagnosis and management of these complications, however, are not standardized and remain a challenge to nurses.

Click here to view more courses on mycme.com.

Stay Connected

Join us on Facebook

Watch us on YouTube

Hematology/Oncology Links

myCME cancer programs

Two myCME Webcasts, Management of Metastatic Melanoma and Management of Early Melanoma and Atypical Spitz Tumors, provide health care professionals with current and relevant research, treatment options, clinical data, guidance, and resources to optimize melanoma detection, management, patient care, and outcomes. Each Webcast offers 1.0 AMA PRA Category 1 Credit.